Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche To Appeal Native Taq Ruling To Defend Scientific Integrity

This article was originally published in The Gray Sheet

Executive Summary

Roche Molecular Systems and parent company Hoffman-La Roche intend to appeal a Dec. 7 San Francisco federal district court ruling that the firm's native Taq polymerase patent is "unenforceable" because of inequitable conduct during Cetus Corp.' s patent application process in 1986, Roche said Dec. 8.

You may also be interested in...



PCR Enzyme Patent Dispute Leads To Overbilling Charges; DoJ Takes A Pass

The Department of Justice says it will not intervene in a Promega civil action alleging that Roche overbilled the government for Taq enzyme-related products, and seeking redress under the False Claims Act

PCR Enzyme Patent Dispute Leads To Overbilling Charges; DoJ Takes A Pass

The Department of Justice says it will not intervene in a Promega civil action alleging that Roche overbilled the government for Taq enzyme-related products, and seeking redress under the False Claims Act

Roche ’818 patent

U.S. Patent and Trademark Office will reexamine Roche's Thermus aquaticus (Taq) DNA polymerase patent to "determine whether any prior art cited in recent litigation poses any new question of patentability," the firm announces April 12. The enforceability of the patent is currently under review by the U.S. Court of Appeals in Washington, D.C. after being challenged by Promega Corp. (1"The Gray Sheet" Dec. 13, 1999, p. 16)...

Related Content

UsernamePublicRestriction

Register

MT012712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel